Home

Merck & Co (MRK)

85.70
-0.29 (-0.34%)
NYSE · Last Trade: Oct 13th, 9:54 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close85.99
Open85.65
Bid85.45
Ask85.80
Day's Range85.24 - 86.46
52 Week Range73.31 - 111.58
Volume6,553,970
Market Cap216.94B
PE Ratio (TTM)13.20
EPS (TTM)6.5
Dividend & Yield3.240 (3.78%)
1 Month Average Volume13,727,965

Chart

About Merck & Co (MRK)

Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More

News & Press Releases

Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to market. By combining generative artificial intelligence with high-throughput wet lab technologies, Absci aims to drastically cut down the time and cost associated
Via MarketMinute · October 13, 2025
1 Cash-Producing Stock to Target This Week and 2 That Underwhelm
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via StockStory · October 13, 2025
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Riskmarketbeat.com
Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype?
Via MarketBeat · October 13, 2025
Dow Jones Soars on Trump's Tariff Remarks, Signaling Market Volatility Amidst Trade Policy Shifts
New York, NY – October 13, 2025 – The Dow Jones Industrial Average has experienced significant upward momentum in recent months, notably jumping by hundreds of points on multiple occasions in early 2025, following pivotal statements from President Donald Trump regarding his administration's tariff policies. These sudden rallies underscore the profound sensitivity
Via MarketMinute · October 13, 2025
Tesla To $300? Here Are 10 Top Analyst Forecasts For Mondaybenzinga.com
Via Benzinga · October 13, 2025
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?fool.com
Now may be the time to invest in drug companies, as they just slipped the tariff noose.
Via The Motley Fool · October 13, 2025
Global Markets Diverge: Asian Shares Stumble Amid US-China Trade Tensions, While Wall Street Futures Rebound
Global financial markets are currently experiencing a significant divergence, with Asian shares facing considerable pressure due to escalating US-China trade tensions, while Wall Street futures have staged a notable rebound. This split reaction, observed around October 12, 2025, highlights the immediate and often contrasting interpretations of heightened geopolitical risks and
Via MarketMinute · October 12, 2025
Inflation's Shadow Lengthens: September CPI Ignites Fed Caution Amidst Government Shutdown
Washington D.C., October 10, 2025 – The financial markets are bracing for impact as the September 2025 Consumer Price Index (CPI) report looms, a critical piece of economic data that promises to shine a harsh light on persistent inflation. This report, due for release amidst an ongoing government shutdown, is
Via MarketMinute · October 10, 2025
UK Weighs 25% Rise In Drug Prices As Pharma Giants Pause Investmentsbenzinga.com
UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies.
Via Benzinga · October 10, 2025
Pfizer (NYSE:PFE) Marks 348th Consecutive Dividend Payment: A Pillar of Stability Amidst Transformation
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This latest payout marks a significant milestone: the company's 348th consecutive quarterly dividend. The unwavering consistency of
Via MarketMinute · October 9, 2025
Zoetis (NYSE:ZTS) Signals Robust Health with Q4 2025 Dividend Declaration, Bolstering Investor Confidence in Animal Health Sector
Parsippany, N.J. – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today declared a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This proactive announcement, made well in advance of the payment date, underscores the company's consistent commitment to shareholder
Via MarketMinute · October 9, 2025
Zoetis (NYSE:ZTS) Declares $0.50 Q4 2025 Dividend, Signaling Robust Animal Health Market
NEW YORK, NY – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today announced a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This declaration, made on the current date of October 9, 2025, underscores the company's consistent commitment to shareholder
Via MarketMinute · October 9, 2025
Pfizer's 348th Consecutive Dividend: A Beacon of Stability Amidst Industry Headwinds
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This payment marks a significant milestone as the company's 348th consecutive quarterly dividend, a testament to its
Via MarketMinute · October 9, 2025
Behind the Scenes of Merck & Co's Latest Options Trendsbenzinga.com
Via Benzinga · October 9, 2025
5 Healthcare Plays Powering the Sector’s Big Comebackmarketbeat.com
After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.
Via MarketBeat · October 9, 2025
Merck to Present New Data from HIV Treatment and Prevention Pipeline at European AIDS Conference 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that it will present new findings from its HIV treatment and prevention pipeline at the 20th European AIDS Conference (EACS 2025) taking place Oct.15-18, 2025, in Paris, France. The company’s presentations will include:
By Merck & Co., Inc. · Via Business Wire · October 9, 2025
Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Earlier Stages of Disease at ESMO 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 abstracts across more than 20 types of cancer and multiple treatment settings from the company’s broad and differentiated portfolio and pipeline will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, from Oct. 17-21. These data showcase Merck’s commitment to rapidly advancing research across multiple tumor types to help improve outcomes for patients across stages of cancer.
By Merck Sharp & Dohme · Via Business Wire · October 9, 2025
MERCK INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Merck (MRK) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · October 8, 2025
Merck, Doctors Reject Proposal To Break Up Combined MMR Vaccinebenzinga.com
Merck and health experts push back against U.S. officials' call to split the MMR vaccine, warning it could delay immunizations and weaken immune response.
Via Benzinga · October 7, 2025
How Arcus Biosciences Aims To Take On Merck In Cancer Treatmentinvestors.com
Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug.
Via Investor's Business Daily · October 7, 2025
Merck Completes Acquisition of Verona Pharma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) acquisition. Verona Pharma is now a wholly-owned subsidiary of Merck and the American Depositary Shares (ADS) of Verona Pharma will no longer be listed or traded on the Nasdaq Global Market.
By Merck & Co., Inc. · Via Business Wire · October 7, 2025
Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced it has initiated three Phase 2b trials evaluating the safety and efficacy of tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor (TNF)-like cytokine 1A (TL1A), in patients with three immune-mediated inflammatory diseases:
By Merck Sharp & Dohme · Via Business Wire · October 6, 2025
1 Monster Stock in the Making to Buy and Holdfool.com
This biotech company was relatively unknown a few years ago.
Via The Motley Fool · October 5, 2025
Wall Street Hits Record Highs As Rate Cut Bets Offset Shutdown: This Week In Marketsbenzinga.com
S&P500, Nasdaq100, Dow Jones, and Russell 2000 all hit record highs as investors focus on corporate optimism, monetary easing and AI tech.
Via Benzinga · October 3, 2025
Merck & Co's Options: A Look at What the Big Money is Thinkingbenzinga.com
Via Benzinga · October 3, 2025